Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.

Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, Arnold AG, Yu KH, Varghese AM, Kelsen DP, Brenner R, Kaufmann E, Ravichandran V, Mukherjee S, Berger MF, Hyman DM, Klimstra DS, Abou-Alfa GK, Tjan C, Covington C, Maynard H, Allen PJ, Askan G, Leach SD, Iacobuzio-Donahue CA, Robson ME, Offit K, Stadler ZK, O'Reilly EM.

J Natl Cancer Inst. 2018 Feb 28. doi: 10.1093/jnci/djy024. [Epub ahead of print]

PMID:
29506128
2.

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA Jr, Mandelker D, Yu KH, Zervoudakis A, Kelsen DP, Iacobuzio-Donahue CA, Klimstra DS, Saltz LB, Sahin IH, O'Reilly EM.

Clin Cancer Res. 2018 Mar 15;24(6):1326-1336. doi: 10.1158/1078-0432.CCR-17-3099. Epub 2018 Jan 24.

PMID:
29367431
3.

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.

Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.

PMID:
29338080
4.

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.

Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.

PMID:
29223478
5.

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.

Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K.

JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137.

6.

Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome.

Salo-Mullen EE, Lynn PB, Wang L, Walsh M, Gopalan A, Shia J, Tran C, Man FY, McBride S, Schattner M, Zhang L, Weiser MR, Stadler ZK.

Fam Cancer. 2018 Jan;17(1):71-77. doi: 10.1007/s10689-017-0006-x.

PMID:
28555354
7.

Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.

Hamilton JG, Genoff MC, Salerno M, Amoroso K, Boyar SR, Sheehan M, Fleischut MH, Siegel B, Arnold AG, Salo-Mullen EE, Hay JL, Offit K, Robson ME.

Breast Cancer Res Treat. 2017 Apr;162(2):297-306. doi: 10.1007/s10549-017-4123-x. Epub 2017 Feb 1.

8.

CDH1 Missense Variant c.1679C>G (p.T560R) Completely Disrupts Normal Splicing through Creation of a Novel 5' Splice Site.

Yelskaya Z, Bacares R, Salo-Mullen E, Somar J, Lehrich DA, Fasaye GA, Coit DG, Tang LH, Stadler ZK, Zhang L.

PLoS One. 2016 Nov 23;11(11):e0165654. doi: 10.1371/journal.pone.0165654. eCollection 2016.

9.

Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients.

Strong VE, Gholami S, Shah MA, Tang LH, Janjigian YY, Schattner M, Selby LV, Yoon SS, Salo-Mullen E, Stadler ZK, Kelsen D, Brennan MF, Coit DG.

Ann Surg. 2017 Dec;266(6):1006-1012. doi: 10.1097/SLA.0000000000002030.

PMID:
27759617
10.

Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group.

Corines MJ, Hamilton JG, Glogowski E, Anrig CA, Goldberg R, Niehaus K, Salo-Mullen E, Harlan M, Sheehan MR, Trottier M, Ahsraf A, Tran C, Jacobs L, Rau-Murthy R, Lincoln AG, Robson ME, Guillem JG, Markowitz AJ, Offit K, Stadler ZK.

J Genet Couns. 2017 Apr;26(2):232-243. doi: 10.1007/s10897-016-0015-1. Epub 2016 Oct 12.

11.

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.

Stadler ZK, Battaglin F, Middha S, Hechtman JF, Tran C, Cercek A, Yaeger R, Segal NH, Varghese AM, Reidy-Lagunes DL, Kemeny NE, Salo-Mullen EE, Ashraf A, Weiser MR, Garcia-Aguilar J, Robson ME, Offit K, Arcila ME, Berger MF, Shia J, Solit DB, Saltz LB.

J Clin Oncol. 2016 Jun 20;34(18):2141-7. doi: 10.1200/JCO.2015.65.1067. Epub 2016 Mar 28.

12.

Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.

Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM.

Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):893-905. doi: 10.1586/17474124.2016.1153424. Epub 2016 Feb 26. Review.

13.

Identification of germline genetic mutations in patients with pancreatic cancer.

Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, Reidy DL, Epstein AS, Lincoln A, Saldia A, Jacobs LM, Rau-Murthy R, Zhang L, Kurtz RC, Saltz L, Offit K, Robson ME, Stadler ZK.

Cancer. 2015 Dec 15;121(24):4382-8. doi: 10.1002/cncr.29664. Epub 2015 Oct 6.

14.

Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant.

Schrader KA, Stratton KL, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T, Shah S, Rau-Murthy R, Manschreck C, Salo-Mullen E, Otegbeye E, Corines M, Zhang L, Norton L, Hudis C, Klein RJ, Kauff ND, Robson M, Stadler ZK, Haber DA, Lipkin SM, Friedman E, Foulkes WD, Altshuler D, Vijai J, Offit K.

J Clin Oncol. 2016 Mar 10;34(8):e61-7. doi: 10.1200/JCO.2013.50.0272. Epub 2014 Jun 30. No abstract available.

PMID:
24982446
15.

Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families.

Arnold AG, Otegbeye E, Fleischut MH, Glogowski EA, Siegel B, Boyar SR, Salo-Mullen E, Amoroso K, Sheehan M, Berliner JL, Stadler ZK, Kauff ND, Offit K, Robson ME, Zhang L.

Breast Cancer Res Treat. 2014 Jun;145(3):625-34. doi: 10.1007/s10549-014-2987-6. Epub 2014 May 14.

PMID:
24825132
16.

Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome.

Salo-Mullen EE, Shia J, Brownell I, Allen P, Girotra M, Robson ME, Offit K, Guillem JG, Markowitz AJ, Stadler ZK.

Fam Cancer. 2014 Sep;13(3):459-67. doi: 10.1007/s10689-014-9709-4.

PMID:
24609522
17.

The genetic counselor: an important surgical ally in the optimal care of the cancer patient.

Salo-Mullen EE, Guillem JG.

Adv Surg. 2012;46:137-53. Review.

PMID:
22873037
18.

Juvenile polyposis syndrome presenting with familial gastric cancer and massive gastric polyposis.

Stadler ZK, Salo-Mullen E, Zhang L, Shia J, Bacares R, Power DG, Weiser M, Coit D, Robson ME, Offit K, Schattner M.

J Clin Oncol. 2012 Sep 1;30(25):e229-32. doi: 10.1200/JCO.2012.41.7949. Epub 2012 Jul 23. No abstract available.

PMID:
22826269
19.

The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized.

Steinhagen E, Guillem JG, Chang G, Salo-Mullen EE, Shia J, Fish S, Stadler ZK, Markowitz AJ.

Clin Colorectal Cancer. 2012 Dec;11(4):304-8. doi: 10.1016/j.clcc.2012.01.006. Epub 2012 Mar 15.

PMID:
22425061
20.

Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection.

Steinhagen E, Shia J, Markowitz AJ, Stadler ZK, Salo-Mullen EE, Zheng J, Lee-Kong SA, Nash GM, Offit K, Guillem JG.

J Am Coll Surg. 2012 Jan;214(1):61-7. doi: 10.1016/j.jamcollsurg.2011.10.004.

PMID:
22192923
21.

An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.

Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D'Adamo DR, Salo-Mullen E, Robson ME, Allen PJ, Kurtz RC, O'Reilly EM.

Oncologist. 2011;16(10):1397-402. doi: 10.1634/theoncologist.2011-0185. Epub 2011 Sep 20.

22.

De novo CDH1 mutation in a family presenting with early-onset diffuse gastric cancer.

Shah MA, Salo-Mullen E, Stadler Z, Ruggeri JM, Mirander M, Pristyazhnyuk Y, Zhang L.

Clin Genet. 2012 Sep;82(3):283-7. doi: 10.1111/j.1399-0004.2011.01744.x. Epub 2011 Aug 2.

PMID:
21696387
23.

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.

Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME.

Cancer. 2012 Jan 15;118(2):493-9. doi: 10.1002/cncr.26191. Epub 2011 May 19.

24.

Germline PALB2 mutation analysis in breast-pancreas cancer families.

Stadler ZK, Salo-Mullen E, Sabbaghian N, Simon JA, Zhang L, Olson SH, Kurtz R, Offit K, Foulkes WD, Robson ME, Tischkowitz M.

J Med Genet. 2011 Aug;48(8):523-5. doi: 10.1136/jmg.2010.087379. Epub 2011 Mar 17.

PMID:
21415078

Supplemental Content

Loading ...
Support Center